
Sign up to save your podcasts
Or


Send a text
SPLENDOR lead author Ali Amirian, the Surfers and audience member Shardool Jain of Altrix Bio debate whether and when bariatric surgery might become first line therapy for multi-morbid metabolic patients.
Dr. Jain takes the position that for many patients with metabolic co-morbidities, drugs tends not to work over time, so why not go to bariatric earlier in therapy...even in first line? Panelists disagree to varying degrees. After Dr. Jain leaves, the group answers Roger's question about what they anticipate might be long-acting effects of this pivotal study.
By SurfingNASH.com3.9
2424 ratings
Send a text
SPLENDOR lead author Ali Amirian, the Surfers and audience member Shardool Jain of Altrix Bio debate whether and when bariatric surgery might become first line therapy for multi-morbid metabolic patients.
Dr. Jain takes the position that for many patients with metabolic co-morbidities, drugs tends not to work over time, so why not go to bariatric earlier in therapy...even in first line? Panelists disagree to varying degrees. After Dr. Jain leaves, the group answers Roger's question about what they anticipate might be long-acting effects of this pivotal study.

32,261 Listeners

30,685 Listeners

9,759 Listeners

103 Listeners

21,112 Listeners

3,379 Listeners

113,483 Listeners

56,981 Listeners

9,563 Listeners

7,961 Listeners

10,223 Listeners

6,445 Listeners

0 Listeners

421 Listeners

721 Listeners